CAR-T ARI-0001 shows high response rates in adult patients with acute lymphoblastic leukemia
Developed by Clínic-IDIBAPS teams as part of the Clínic Barcelona Comprehensive Cancer Centre, this treatment confirms its therapeutic potential in a1
Developed by Clínic-IDIBAPS teams as part of the Clínic Barcelona Comprehensive Cancer Centre, this treatment confirms its therapeutic potential in a1
CAR T-cell therapy, a revolutionary technology originally developed for blood cancers, may also help in restoring the immune system in severe autoimm1
On Tuesday, November 18, the consortium of the European project MILenARI (Mediterranean International Lentivirus ARI) held its inaugural meeting onli1
A study led by the Clínic Barcelona Comprehensive Cancer Center —a center driven by Clínic-IDIBAPS and the University of Barcelona (UB)— demonstrates1
Researchers from Clínic-IDIBAPS, within the Clínic Barcelona Comprehensive Cancer Center, and the spin-off Gyala Therapeutics have coordinated a stud1
A study led by the Clínic-IDIBAPS reveals that the microbiota can predict and enhance patient response to one of the most innovative immunotherapies1
The prognosis for patients with systemic lupus erythematosus (SLE) has improved dramatically over the last 50 years. Thus, from a 5-year mortality ra1
The campaign’s challenge was to collect 12,000 book reviews, and it exceeded its goal. A total of 15,399 reviews were received.
Hospital Clínic-IDIBAPS is the only hospital in Europe to have fully developed two academic CAR T-cell therapies that have been approved by a regulat1
Girem Full! (Let's Turn the Page!) is a charity event that aims to raise funds for cancer immunotherapy research by promoting reading.